Fundraising Fox
Aegle Therapeutics
Woburn, US · Delaware corporation · 5 known investors
Find your way into Aegle Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Melissa Rayner to introduce you to Shelley A. Hartman
You →Melissa · together at University of Miami, Miller School of Medicine →Shelley
Ask Jamie Chen to introduce you to Heidi Kempinski
You →Jamie · together at Zenas Biopharma →Heidi
Sign up to find every way you can get introduced to Aegle Therapeutics
- Your email: who you already know at Aegle Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Aegle Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
Founders & leadership
Board
Investors · 5
How we know: DEFTA Partners's portfolio page · Not right? Tell us
How we know: New World Angels's portfolio page · funding news · newworldangels.com · Not right? Tell us
How we know: Ocean Azul Partners's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.2M disclosed across 3 of 4 rounds · 2020–2026
▶$2.3MraisedAug 2026 · 17 investors · BiotechnologyRule 506(b)
- Shelley HartmanExecutive Officer, Director
- Scott BraunsteinDirector
- Leon MoulderDirector
- Evangelos BadiavasDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$455.7KraisedMar 2026 · 10 investors · BiotechnologyRule 506(b)
- Evangelos BadiavasDirector
- Shelley HartmanExecutive Officer, Director
- David SchimelDirector
- Scott BraunsteinDirector
- Leon MoulderDirector
- Mikio TanjiDirector
- Steve O'HaraDirector
- Offering amount
- $700K
- Amount sold
- $455.7K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.5MraisedJul 2020 · 8 investors · BiotechnologyRule 506(b)
- Shelley HartmanExecutive Officer, Director
- Evangelos BadiavasExecutive Officer, Director
- Robert Williamson, Jr.Executive Officer, Director
- David SchimelDirector
- Robert RyanDirector
- Elona BaumDirector
- Leon Moulder, Jr.Director
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Companies working in the same space as Aegle Therapeutics.
In the news
Frequently asked questions
- What does Aegle Therapeutics do?
- Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
- Who founded Aegle Therapeutics?
- Aegle Therapeutics was founded by Shelley A. Hartman, Evangelos V. Badiavas.
- Who are Aegle Therapeutics's investors?
- Aegle Therapeutics's investors include DEFTA Partners, New World Angels, Ocean Azul Partners, DeepWork Capital, DEFTA HEALTHCARE TECHNOLOGIES.
- How much funding has Aegle Therapeutics raised?
- Aegle Therapeutics has disclosed $9.2M raised across 3 of its 4 known rounds.
- Where is Aegle Therapeutics headquartered?
- Aegle Therapeutics is headquartered in Woburn, US.